Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

Pharma major Cipla has secured final approval from the US health regulator for its generic albuterol sulfate inhalation aerosol. This marks a significant milestone for Cipla, reinforcing its leadership in the respiratory segment. The approval enhances Cipla's US portfolio, offering a therapeutic equivalent to a key branded medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2C6WKwh
via IFTTT

Read More

USFDA issues Form-483 with 5 observations to Ajanta Pharma's Paithan facility

Ajanta Pharma said the US FDA has issued Form-483 with five observations after inspecting its Paithan manufacturing facility in Maharashtra from April 13–21, 2026. The company stated it will respond within the stipulated timeframe, while noting that Form-483 is issued when inspectors observe potential regulatory violations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WjGbXS1
via IFTTT

Read More

Lupin launches generic anti-diabetic tablets in US

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydrochloride extended-release tablets. The US Food and Drug Administration approved the drug. Lupin's product is bioequivalent to Xigduo XR. This launch offers a new treatment option for diabetic patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hzWucXo
via IFTTT

Read More

Govt's ammonia rule to hurt pharma cos as directive restricts sale of surplus to fertiliser firms

India’s pharmaceutical industry faces a potential raw material crunch after the government restricted surplus ammonia supply to fertiliser use. Drugmakers warn the move could disrupt API production, cause medicine shortages and impact exports, as ammonia is a critical input and alternative sourcing options remain limited.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ydy0Mio
via IFTTT

Read More

Obesity drug market to gain as Indians pop the pill and Chinese bring more

India's obesity treatment market is set for a major shift by year-end. A wave of oral GLP1 weight-loss pills, including those from China, will soon be available. These pills offer a cheaper and easier alternative to injections. Experts anticipate greater patient adoption due to convenience and affordability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3cnR9DY
via IFTTT

Read More

Counterfeit Mounjaro case: Eli Lilly issues statement after Gurugram drug racket exposed

Gurugram's law enforcement has taken a bold step by breaking up a ring creating counterfeit Mounjaro injections, with two individuals now in custody for their role in the illicit trade of diabetes and obesity medications. The illicit enterprise involved importing raw materials from China and manufacturing the injections in a private home.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5N0ywz8
via IFTTT

Read More

Bain Capital sole contender for Vitabiotics buy

TPG, EQT chose to opt out from final bids. UK’s largest nutraceutical company with operations in India, UK, China exports to 100 countries. Company was originally valued at £900 mn.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/841t3eO
via IFTTT

Read More